

## Supplementary Material\*

Li Y, Marks SM, Beeler Asay GR, et al. Effectiveness and cost-effectiveness of expanded targeted testing and treatment of latent tuberculosis infection among the Medicare population in 2022. *Ann Intern Med*. 7 February 2025. [Epub ahead of print]. doi:10.7326/ANNALS-24-00870

### Table of Contents

|                                                                                                                                                                                                                                                                                                                                                                                                    |           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| <i>eMethods 1. Definitions and data sources of the fifteen risk factors. ....</i>                                                                                                                                                                                                                                                                                                                  | <b>2</b>  |
| <i>eMethods 2. Components of cost perspectives. ....</i>                                                                                                                                                                                                                                                                                                                                           | <b>4</b>  |
| <i>Supplement Table 1. Definitions of risk factors for LTBI testing. ....</i>                                                                                                                                                                                                                                                                                                                      | <b>5</b>  |
| <i>Supplement Table 2. Model inputs parameters. ....</i>                                                                                                                                                                                                                                                                                                                                           | <b>7</b>  |
| <i>Supplement Table 3. Impact inventory form. ....</i>                                                                                                                                                                                                                                                                                                                                             | <b>12</b> |
| <i>Supplement Table 4. Number of populations, LTBI prevalence, and Medicare population with LTBI of Medicare population aged 65 years by risk factor in 2022. ....</i>                                                                                                                                                                                                                             | <b>13</b> |
| <i>Supplement Table 5. Estimated numbers of LTBI treatment initiated, TB cases averted, TB deaths averted, and QALYs gained for LTBI testing and treatment intervention for Medicare-eligible individuals aged 65 years and older and for individuals aged 65 years in 2022. ....</i>                                                                                                              | <b>14</b> |
| <i>Supplement Table 6. Compared with no intervention, the estimated numbers of incremental costs (million in 2021 USD) from a TB service perspective, a healthcare perspective, and a societal perspective, for LTBI testing and treatment intervention for Medicare-eligible individuals aged 65 years and older, and for newly eligible for Medicare individuals aged 65 years in 2022. ....</i> | <b>15</b> |
| <i>Supplement Table 7. Partial rank correlation coefficients identified parameters ordered from greatest to least influence on cost-effectiveness results. ....</i>                                                                                                                                                                                                                                | <b>16</b> |
| <i>Supplement Table 8. Compared with no intervention, the estimated incremental cost-effectiveness ratios by risk factor among the Medicare-eligible population aged 65 years or older in 2022. ....</i>                                                                                                                                                                                           | <b>18</b> |
| <i>Supplement Table 9. Compared with no intervention, the estimated incremental cost-effectiveness ratios by risk factor among the Medicare-eligible population aged 65 years in 2022. ....</i>                                                                                                                                                                                                    | <b>19</b> |
| <i>Supplement Table 10. Compared with no intervention, the estimated incremental cost-effectiveness ratios by risk factor among the Medicare-eligible population aged 65 years or older in 2022, with an alternative source for the base LTBI reactivation rate parameter. ....</i>                                                                                                                | <b>20</b> |

|                                                                                                                                                                                                                                                                                                                                            |           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| <i>Supplement Table 11. Compared with no intervention, the estimated incremental cost-effectiveness ratios by risk factor among the Medicare-eligible population aged 65 years or older in 2022, with 100% of accepting LTBI testing, 100% of initiating treatment among who diagnosed with LTBI, and 100% of completing therapy. ....</i> | <b>21</b> |
| <i>Supplement Table 12. Compared with no intervention, the estimated incremental cost-effectiveness ratios by risk factor among the Medicare-eligible population aged 65 years or older in 2022, with IGRA and TST tests characteristics from USPSTF(14). ....</i>                                                                         | <b>22</b> |
| <i>Supplement Table 13. Compared with no intervention, the estimated incremental cost-effectiveness ratios by risk factor among the Medicare-eligible population aged 65 years or older in 2022, when considering the consequences of averted secondary TB cases. ....</i>                                                                 | <b>23</b> |
| <i>Supplement Figure 1. Decision tree and Markov model of the lifetime progression of a Medicare cohort for LTBI screening and treatment. ....</i>                                                                                                                                                                                         | <b>24</b> |
| <i>Supplement Figure 2. Cost-effectiveness acceptability curves for the intervention offered to the overall target population aged 65 years and over, and for risk factor Groups A, B, and C. ....</i>                                                                                                                                     | <b>25</b> |
| <i>Supplement Figure 3. Cost-effectiveness acceptability curves for the intervention offered to the overall target population aged 65 years, and for risk factor Groups A, B, and C. ....</i>                                                                                                                                              | <b>26</b> |
| <i>References .....</i>                                                                                                                                                                                                                                                                                                                    | <b>27</b> |

\* This supplementary material was provided by the authors to give readers further details on their article. The material was not copyedited.

## eMethods 1. Definitions and data sources of the fifteen risk factors.

We extracted data from the National Health Interview Survey (NHIS) for 2010-2019,(1) describing the proportion of the US population aged 65 years and over who receive immunosuppressive medications, who have diagnosed diabetes, CKD, cancer of the head or neck or blood, BMI under 20, or are current smokers. We extracted nationally representative cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) for 2010-2019,(2) describing the proportion of the population who had close contact with a person with infectious TB disease, or ESRD. We extracted data from national surveillance reports or published literature(3–9) describing the proportion of the population with a history of homelessness, with a history of incarceration, residing in long-term care facilities, having HIV infection, received organ transplantation, or had a gastrectomy.

We assumed that an individual in our study population could have no more than two risk factors, and estimated the number of individuals with each two-way combination of risk factors. Where no evidence was available on the overlap of risk factors, we assumed they were independently distributed (population fraction with both risk factors equal to the product of the population fraction with each risk factor). We adjusted population size estimates downwards to account for individuals with multiple risk factors for the Group A, B, and C populations, and for the pooled population for all three groups. Each group included individuals with at least one of the risk factors presented, and the total number of individuals at risk for TB in each group was adjusted to account for those with two risk factors within that group. The overall population at risk for TB across all groups was adjusted to account for individuals with any two of the fifteen risk factors across the three groups.

## eMethods 2. Components of cost perspectives.

We estimated costs from three perspectives: a TB service perspective, which includes the costs of LTBI testing and treatment as well as future TB treatment costs (including diagnosis, treatment, and any required hospitalization); a health care sector perspective, including TB service costs as well as healthcare costs unrelated to TB; and a societal perspective, including healthcare costs as well as non-health expenditures (such as food, housing, transportation, and services) and productivity losses. We adopted the societal perspective for the main analysis.<sup>(10)</sup> [Values and distributions are reported in Supplement Table 2, with impact inventory reported in Supplement Table 3.](#)

Supplement Table 1. Definitions of risk factors for LTBI testing.

| Risk factor                                    | Definitions                                                                                                                                                                                                                        | Data sources                                                                                                              | References |
|------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|------------|
| <b>Group A<sup>a</sup></b>                     |                                                                                                                                                                                                                                    |                                                                                                                           |            |
| <i>Non-US-born</i>                             | Includes naturalized citizens and legal permanent residents who receive social security retirement benefits, and who were born in a country other than Canada, Australia, New Zealand, or a country in western or northern Europe. | American Community Survey 2021                                                                                            | (11,12)    |
| <i>History of homelessness</i>                 | Individuals who report having ever been homeless or lived in a shelter.                                                                                                                                                            | Health and Retirement Study (HRS)                                                                                         | (9)        |
| <i>History of incarceration</i>                | Individuals who report having ever spent time in juvenile detention, jail, or prison.                                                                                                                                              | Health and Retirement Study (HRS)                                                                                         |            |
| <i>Long-term care</i>                          | Current users of adult day services center, home health agency, hospice, nursing home, and residential care community.                                                                                                             | Long-term Care Providers and Services Users in the United States, 2015-2016                                               | (3,8)      |
| <b>Group B<sup>b</sup></b>                     |                                                                                                                                                                                                                                    |                                                                                                                           |            |
| <i>Close contact</i>                           | Individuals who ever lived in the same household with someone while that person was sick with TB disease.                                                                                                                          | National Health and Nutrition Examination Survey 2011-2012                                                                | (2)        |
| <i>HIV</i>                                     | Individuals who have diagnosed HIV infection.                                                                                                                                                                                      | Diagnoses of HIV Infection Among Adults Aged 50 Years and Older in United States and Dependent areas 2011-2016, 2014-2018 | (5,13)     |
| <i>Immunosuppressive medications recipient</i> | Individuals who have received medications or treatments during past 6 months that weaken their immune system.                                                                                                                      | National Health Interview Survey 2010-2019                                                                                | (1)        |
| <i>Organ transplant recipient</i>              | Individuals who have received an organ transplant.                                                                                                                                                                                 | National data reported by Organ Procurement and Transplantation Network                                                   | (6)        |
| <b>Group C<sup>c</sup></b>                     |                                                                                                                                                                                                                                    |                                                                                                                           |            |
| <i>Diabetes</i>                                | Individuals who have received a diabetes diagnosis.                                                                                                                                                                                | National Health Interview Survey 2010-2019                                                                                | (1)        |
| <i>End stage renal disease (ESRD)</i>          | Individuals who have diagnosed renal disease with estimated glomerular filtration rate below 15.                                                                                                                                   | National Health and Nutrition Examination Survey 2011-2018                                                                | (2)        |
| <i>Chronic kidney disease</i>                  | Individuals who have diagnosed chronic kidney disease (excluding individuals with ESRD).                                                                                                                                           | National Health Interview Survey 2010-2019                                                                                | (1)        |

| Risk factor            | Definitions                                                                                 | Data sources                                                                                                                                 | References |
|------------------------|---------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|------------|
| <i>Cancer</i>          | Individuals who ever had diagnosed cancer of the head, neck or blood.                       | National Health Interview Survey 2010-2019                                                                                                   | (1)        |
| <i>Gastrectomy</i>     | Individuals who have received a metabolic and bariatric surgery procedure in the past year. | American Society for Metabolic and Bariatric Surgery estimation of metabolic and bariatric procedures performed in the United States in 2016 | (7)        |
| <i>BMI under 20</i>    | Individuals who have a Body Mass Index below 20.                                            | National Health Interview Survey 2010-2019                                                                                                   | (1)        |
| <i>Current smoking</i> | Individuals who have a self-reported smoking status as “current every day/some day smoker”. | National Health Interview Survey 2010-2019                                                                                                   | (1)        |

<sup>a</sup> Group A includes Medicare-eligible persons with one of four factors that the USPSTF(14) recommends for screening and testing for LTBI in the primary care setting.

<sup>b</sup> Group B includes Medicare-eligible persons with one of four factors acknowledged by USPSTF as population at risk for either exposure or progression to TB disease but regularly screened or tested outside of primary care settings.

<sup>c</sup> Group C includes Medicare-eligible persons with one of seven factors associated with increased risk of TB disease who are not specifically included in USPSTF screening recommendations.

Supplement Table 2. Model inputs parameters.

| Variable                                                                                                                                                                                                           | Base-Case Value | Range (95% Uncertainty Interval)‡ | Distribution         | References |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-----------------------------------|----------------------|------------|
| <b>Test Characteristics</b>                                                                                                                                                                                        |                 |                                   |                      |            |
| TST test sensitivity                                                                                                                                                                                               |                 |                                   |                      |            |
| <i>US-born, HIV-negative</i>                                                                                                                                                                                       | 0.726           | 0.622-0.843                       | Beta (44.26, 16.70)  | (15)       |
| <i>US-born, HIV-positive</i>                                                                                                                                                                                       | 0.540           | 0.442-0.643                       | Beta (50.24, 42.80)  | (15)       |
| <i>Non-US-born, HIV-negative</i>                                                                                                                                                                                   | 0.807           | 0.726-0.905                       | Beta (58.77, 14.06)  | (15)       |
| <i>Non-US-born, HIV-positive</i>                                                                                                                                                                                   | 0.570           | 0.496-0.653                       | Beta (86.27, 65.08)  | (15)       |
| TST test specificity                                                                                                                                                                                               |                 |                                   |                      |            |
| <i>US-born, HIV-negative</i>                                                                                                                                                                                       | 0.921           | 0.897-0.943                       | Beta (483.73, 41.49) | (15)       |
| <i>US-born, HIV-positive</i>                                                                                                                                                                                       | 0.965           | 0.953-0.976                       | Beta (941.02, 34.13) | (15)       |
| <i>Non-US-born, HIV-negative</i>                                                                                                                                                                                   | 0.700           | 0.683-0.715                       | Beta (2204.7, 944.9) | (15)       |
| <i>Non-US-born, HIV-positive</i>                                                                                                                                                                                   | 0.885           | 0.707-0.960                       | Beta (19.47, 2.53)   | (15)       |
| IGRA test sensitivity                                                                                                                                                                                              |                 |                                   |                      |            |
| <i>US-born, HIV-negative</i>                                                                                                                                                                                       | 0.780           | 0.650-0.910                       | Beta (29.04, 8.19)   | (15)       |
| <i>US-born, HIV-positive</i>                                                                                                                                                                                       | 0.675           | 0.529-0.817                       | Beta (26.38, 12.70)  | (15)       |
| <i>Non-US-born, HIV-negative</i>                                                                                                                                                                                   | 0.789           | 0.696-0.902                       | Beta (46.15, 12.34)  | (15)       |
| <i>Non-US-born, HIV-positive</i>                                                                                                                                                                                   | 0.591           | 0.471-0.720                       | Beta (34.54, 23.90)  | (15)       |
| IGRA test specificity                                                                                                                                                                                              |                 |                                   |                      |            |
| <i>US-born, HIV-negative</i>                                                                                                                                                                                       | 0.979           | 0.960-0.994                       | Beta (258.61, 5.55)  | (15)       |
| <i>US-born, HIV-positive</i>                                                                                                                                                                                       | 0.958           | 0.944-0.971                       | Beta (807.61, 35.41) | (15)       |
| <i>Non-US-born, HIV-negative</i>                                                                                                                                                                                   | 0.985           | 0.961-0.998                       | Beta (151.56, 2.31)  | (15)       |
| <i>Non-US-born, HIV-positive</i>                                                                                                                                                                                   | 0.931           | 0.739-0.991                       | Beta (11.74, 0.87)   | (15)       |
| <b>Test Characteristics Sensitivity Analysis</b>                                                                                                                                                                   |                 |                                   |                      |            |
| TST test sensitivity                                                                                                                                                                                               |                 |                                   |                      |            |
| <i>Close contact to infectious TB disease; HIV positivity; immunosuppressive medications recipient; organ transplant recipient</i>                                                                                 | 0.800           | 0.740-0.870                       | Beta (114.92, 28.73) | (14,16,17) |
| <i>History of homelessness; history of incarceration; long-term care; diabetes; end stage renal disease; chronic kidney disease; cancer of the head, neck or blood; gastrectomy; BMI under 20; current smoking</i> | 0.810           | 0.760-0.870                       | Beta (156.79, 36.78) | (14,16,17) |
| TST test specificity                                                                                                                                                                                               |                 |                                   |                      |            |
| <i>Close contact to infectious TB disease; HIV positivity; immunosuppressive medications recipient; organ transplant recipient</i>                                                                                 | 0.950           | 0.940-0.970                       | Beta (766.24, 40.33) | (14,16,17) |
| <i>History of homelessness; history of incarceration; long-term care; diabetes; end stage renal disease; chronic kidney disease; cancer of the head, neck or blood; gastrectomy; BMI under 20; current smoking</i> | 0.980           | 0.970-0.990                       | Beta (728.43, 14.87) | (14,16,17) |

| Variable                                                                         | Base-Case Value | Range (95% Uncertainty Interval)‡ | Distribution           | References |
|----------------------------------------------------------------------------------|-----------------|-----------------------------------|------------------------|------------|
| IGRA test sensitivity                                                            | 0.810           | 0.790-0.840                       | Beta (764.69, 179.37)  | (14,17)    |
| IGRA test specificity                                                            | 0.990           | 0.980-0.990                       | Beta (1487.83, 15.03)  | (14,17)    |
| <b>Reactivation rates (per 100 person-years)</b>                                 |                 |                                   |                        |            |
| Base rate of LTBI reactivation in the overall population                         |                 |                                   |                        |            |
| <i>Main analysis</i>                                                             | 0.051           | 0.031-0.102                       | Beta (7.30, 135.9)     | (18)       |
| <b>Sensitivity analysis</b>                                                      | 0.084           | 0.083-0.085                       | Beta (9170, 100000)    | (19)       |
| Rate ratios of LTBI reactivation §:                                              |                 |                                   |                        |            |
| Group A <sup>a</sup>                                                             |                 |                                   |                        | (14)       |
| <i>Non-US-born</i>                                                               | 1               | ----                              | Fixed at 1             | Assumed    |
| <i>History of homelessness</i>                                                   | 1               | ----                              | Fixed at 1             | Assumed    |
| <i>History of incarceration</i>                                                  | 1               | ----                              | Fixed at 1             | Assumed    |
| <i>Long-term care</i>                                                            | 1               | ----                              | Fixed at 1             | Assumed    |
| Group B <sup>b</sup>                                                             |                 |                                   |                        | (20,21)    |
| <i>Close contact to infectious TB</i>                                            | 10.75           | 5.38-16.13                        | Gamma (15.19, 1.41)    | (22)       |
| <b>HIV positivity</b>                                                            | 11.52           | 10.47-12.69                       | Gamma (413.59, 35.90)  | (18)       |
| <i>Immunosuppressive medications recipient</i>                                   | 1.50            | 1.10-1.90                         | Gamma (53.85, 35.90)   | (23)       |
| <b>Organ transplant recipient</b>                                                | 30.00           | 20.00-74.00                       | Gamma (4.57, 0.15)     | (24)       |
| Group C <sup>c</sup>                                                             |                 |                                   |                        | (20,21)    |
| <b>Diabetes</b>                                                                  | 1.60            | 1.47-1.73                         | Gamma (571.52, 358.99) | (18)       |
| <b>End stage renal disease</b>                                                   | 9.80            | 5.38-18.70                        | Gamma (43.74, 30.80)   | (18)       |
| <b>Chronic kidney disease</b>                                                    | 1.42            | 1.01-1.85                         | Gamma (8.14, 0.83)     | (25)       |
| <b>Cancer of the head, neck or blood</b>                                         | 5.86            | 2.93-8.79                         | Gamma (15.19, 2.59)    | (26)       |
| <b>Gastrectomy</b>                                                               | 2.90            | 2.56-3.23                         | Gamma (287.70, 99.21)  | (27)       |
| <i>BMI under 20</i>                                                              | 2.33            | 1.32-4.12                         | Gamma (10.47, 4.49)    | (28)       |
| <i>Current smoking</i>                                                           | 2.07            | 1.80-2.39                         | Gamma (188.97, 91.29)  | (29)       |
| Proportion of individuals with LTBI without a history of prior LTBI treatment    | 0.881           | 0.847-0.915                       | Beta (304.8, 41.2)     | (30)       |
| Proportion of individuals without LTBI without a history of prior LTBI treatment | 0.994           | 0.991-0.997                       | Beta (2500.5, 15.1)    | (30)       |
| <b>LTBI testing and treatment cascade</b>                                        |                 |                                   |                        |            |
| <b>Proportion of LTBI testing and treatment</b>                                  |                 |                                   |                        |            |
| <b>Main analysis</b>                                                             |                 |                                   |                        |            |
| Proportion accepting offer of LTBI testing                                       | 0.762           | 0.722-0.798                       | Beta (366.3, 114.4)    | (31)       |
| Proportion of diagnosed who initiate treatment                                   | 0.762           | 0.750-0.773                       | Beta (4012.8, 1253.3)  | (32)       |
| Proportion of treated who complete therapy                                       | 0.903           | 0.886-0.919                       | Beta (1113.6, 119.6)   | (33)       |
| <b>Sensitivity analysis</b>                                                      |                 |                                   |                        |            |

| Variable                                                       | Base-Case Value | Range (95% Uncertainty Interval)‡ | Distribution            | References |
|----------------------------------------------------------------|-----------------|-----------------------------------|-------------------------|------------|
| Proportion accepting offer of LTBI testing                     | 1.000           | ---                               | Fixed at 1              | Assumed    |
| Proportion of diagnosed who initiate treatment                 | 1.000           | ---                               | Fixed at 1              | Assumed    |
| Proportion of treated who complete therapy                     | 1.000           | ---                               | Fixed at 1              | Assumed    |
| Proportion tested with IGRA among                              |                 |                                   |                         |            |
| <i>US-born</i>                                                 | 0.500           | 0.300-0.700                       | Beta (11.26, 11.26)     | Assumed    |
| <i>Non-US-born</i>                                             | 1.000           | ---                               | Fixed at 1              | Assumed    |
| Proportion tested with TST among                               |                 |                                   |                         |            |
| <i>US-born</i>                                                 | 0.500           | 0.300-0.700                       | Beta (11.26, 11.26)     | Assumed    |
| <i>Non-US-born</i>                                             | 0               | ---                               | Fixed at 0              | Assumed    |
| Treatment efficacy                                             | 0.930           | 0.850-0.980                       | Beta (6.45, 3.63)       | (34–36)    |
| Treatment side effects                                         |                 |                                   |                         |            |
| <i>Probability of hepatotoxicity</i>                           | 0.003           | 0.000-0.010                       | Beta (1.22, 406.76)     | (35)       |
| <i>Mortality among individuals experiencing hepatotoxicity</i> | 0.00014         | 0.000-0.00028                     | Beta (3.57, 26212.5)    | (37,38)    |
| <b>Mortality rate ratios for individual conditions</b>         |                 |                                   |                         |            |
| <b>TB</b>                                                      |                 |                                   |                         |            |
| <i>Age 65-74 years</i>                                         | 10.28           | 9.98-10.61                        | Lognormal (2.33, 0.015) | (39)       |
| <i>Age 75-84 years</i>                                         | 7.02            | 6.84-7.21                         | Lognormal (1.95, 0.013) | (39)       |
| <i>Age 85 years and older</i>                                  | 4.88            | 4.73-5.03                         | Lognormal (1.58, 0.016) | (39)       |
| <b>Group A<sup>a</sup></b>                                     |                 |                                   |                         | (14)       |
| <i>Non-US-born</i>                                             | 1               | ----                              | Fixed at 1              | Assumed    |
| <i>History of homelessness</i>                                 | 1.82            | 1.23-2.68                         | Gamma (24.03, 13.21)    | (40)       |
| <i>History of incarceration</i>                                | 1               | ----                              | Fixed at 1              | Assumed    |
| <i>Long-term care</i>                                          | 1.196           | 1.175-1.217                       | Gamma (297.31, 270.28)  | (41)       |
| <b>Group B<sup>b</sup></b>                                     |                 |                                   |                         | (14,20)    |
| <i>Close contact</i>                                           | 1               | ----                              | Fixed at 1              | Assumed    |
| <i>HIV</i>                                                     | 2.30            | 1.15-3.45                         | Gamma (15.19, 6.60)     | Assumed    |
| <i>Immunosuppressive medications recipient</i>                 | 2.00            | 1.00-3.00                         | Gamma (15.19, 7.60)     | Assumed    |
| <i>Organ transplant recipient</i>                              | 4.00            | 2.00-6.00                         | Gamma (15.19, 3.80)     | Assumed    |
| <b>Group C<sup>c</sup></b>                                     |                 |                                   |                         | (14,20)    |
| <i>Diabetes</i>                                                | 2.00            | 1.50-3.00                         | Gamma (16.03, 8.44)     | (42)       |
| <i>End stage renal disease</i>                                 | 4.06            | 3.33-4.95                         | Gamma (11.44, 7.48)     | (43)       |
| <i>Chronic kidney disease</i>                                  | 1.53            | 1.01-2.77                         | Gamma (96.34, 23.73)    | (43)       |
| <i>Cancer of the head, neck or blood</i>                       | 2.00            | 1.00-3.00                         | Gamma (15.19, 7.60)     | Assumed    |
| <i>Gastrectomy</i>                                             | 2.00            | 1.00-3.00                         | Gamma (15.19, 7.60)     | Assumed    |
| <i>BMI under 20</i>                                            | 2.05            | 1.37-3.07                         | Gamma (22.17, 10.81)    | (44)       |

| Variable                                                                | Base-Case Value                  | Range (95% Uncertainty Interval)‡ | Distribution                          | References |
|-------------------------------------------------------------------------|----------------------------------|-----------------------------------|---------------------------------------|------------|
| <i>Current smoking</i>                                                  | 1.83                             | 1.65-2.03                         | Gamma (356.19, 194.64)                | (45)       |
| Mortality rates <sup>§</sup>                                            | Stratified by age, race, and sex | ---                               | Fixed as reported in the US lifetable | (46)       |
| <b>Utility weights</b>                                                  |                                  |                                   |                                       |            |
| <i>Untreated LTBI</i>                                                   | 1.000                            | ----                              | Fixed at 1                            | Assumed    |
| <i>LTBI treatment with no hepatotoxicity</i>                            | 1.000                            | ----                              | Fixed at 1                            | (47)       |
| <i>LTBI treatment with hepatotoxicity</i>                               | 0.750                            | 0.650-0.850                       | Beta (52.76, 17.59)                   | (48)       |
| <i>TB disease and treatment</i>                                         | 0.760                            | 0.700-0.820                       | Beta (146.64, 46.31)                  | (47)       |
| <b>Duration of health states (years)</b>                                |                                  |                                   |                                       |            |
| Duration of TB disease prior to TB treatment                            | 0.25                             | 0.125-0.50                        | Beta (11.10, 33.31)                   | Assumed    |
| Duration of TB treatment                                                | 0.75                             | ----                              | Fixed at 0.75                         | Assumed    |
| Duration from TB index case to secondary cases                          | 5.20                             | 2.60-7.80                         | Gamma (15.19, 2.92)                   | (49)       |
| Numbers of secondary TB disease cases per index TB case                 | 0.165                            | 0.0825-0.2475                     | Beta (12.50, 63.25)                   | (49)       |
| <b>Costs (in 2021 USD)</b>                                              |                                  |                                   |                                       |            |
| <b>Intervention costs</b>                                               |                                  |                                   |                                       |            |
| Initial risk assessment cost                                            | \$0.00                           | ----                              | Fixed at 0                            | Assumed    |
| TST testing                                                             | \$9.83                           | \$4.92-\$14.74                    | Gamma (15.19, 1.55)                   | (50)       |
| IGRA testing                                                            | \$63.18                          | \$31.59-\$94.76                   | Gamma (15.19, 0.24)                   | (50)       |
| Ruling out TB disease before treatment initiation (Chest X-ray, 2 view) | \$35.22                          | \$17.61-\$52.83                   | Gamma (15.19, 0.43)                   | (50)       |
| Total cost of LTBI treatment with 3HP SAT*                              | \$419.95                         | \$209.98-\$629.93                 | Gamma (42.02, 0.10)                   | (51,52)    |
| Total cost of LTBI treatment with 4R SAT*                               | \$372.05                         | \$186.02-\$558.07                 | Gamma (37.23, 0.10)                   | (51,52)    |
| Proportion of treatment with 4R                                         | 0.740                            | 0.610-0.870                       | Beta (31.13, 10.94)                   | (53)       |
| Direct treatment costs non-MDR TB                                       | \$20,601                         | \$10,301-\$30,902                 | Gamma (2061.4, 0.10)                  | (54)       |
| Direct treatment costs MDR TB                                           | \$185,703                        | \$92,851-\$278,554                | Gamma (18581.9, 0.010)                | (55)       |
| Direct treatment costs XDR TB                                           | \$578,667                        | \$289,333-\$868,000               | Gamma (57902.8, 0.010)                | (55)       |
| Proportion of TB that is MDR TB#                                        | 0.0078                           | 0.00375-0.01175                   | Beta (14.31, 1820.5)                  | (56)       |
| Proportion of TB that is XDR TB#                                        | 0.0001                           | 0.00005-0.00015                   | Beta (10.00, 99999.9)                 | (56)       |
| <b>Patient productivity losses</b>                                      |                                  |                                   |                                       |            |
| Initial clinic visit                                                    | \$48.94                          | \$24.47-\$73.41                   | Gamma (15.19, 0.31)                   | (52)       |
| Follow-up clinic visit                                                  | \$28.70                          | \$14.35-\$43.06                   | Gamma (15.18, 0.53)                   | (52)       |
| Probability of hospitalization with LTBI treatment with 3HP             | 0.003                            | 0.0015-0.0045                     | Beta (15.14, 5032.3)                  | (57)       |
| Time losses due to outpatient services (in years)                       | 0.019                            | 0.0095-0.0285                     | Beta (14.88, 768.39)                  | (52)       |

| Variable                                               | Base-Case Value                         | Range (95% Uncertainty Interval)‡ | Distribution                             | References |
|--------------------------------------------------------|-----------------------------------------|-----------------------------------|------------------------------------------|------------|
| Probability of hospitalization with TB                 | 0.49                                    | 0.245-0.735                       | Beta (7.09, 7.38)                        | (52)       |
| Average duration of hospitalization with TB (in years) | 0.066                                   | 0.033-0.099                       | Beta (14.12, 199.77)                     | (52)       |
| Annual productivity†                                   | Stratified by age and sex               | ----                              | Fixed as reported in the reference study | (57)       |
| Average annual expenditures                            | Stratified by age                       | ----                              | Fixed as reported in the reference study | (58)       |
| Healthcare costs unrelated to TB                       | Stratified by age and health conditions | ----                              | Fixed as reported in the reference study | (59–62)    |

‡ Where measures of uncertainty were not available for a given parameter, we assumed a 95% interval equivalent to +/- 50% of the point estimate.

§ For individuals with multiple risk factors, we applied the risk factor with higher rate ratio.

<sup>a</sup> Group A included those Medicare-eligible persons with one of four factors whom the USPSTF(14) recommends for screening and testing in the primary care setting for LTBI.

<sup>b</sup> Group B included those Medicare-eligible persons with one of four factors acknowledged by USPSTF as populations at risk for either exposure or progression to TB disease but regularly screened or tested outside of primary care settings.

<sup>c</sup> Group C included those Medicare-eligible persons with one of seven factors associated with increased risk of TB disease who are not specifically part of the USPSTF screening recommendation.

<sup>§</sup> We assumed that mortality rates for non-US-born persons are same as the general US population, by sex and age group. We assumed that mortality rates for Non-Hispanic Other persons are same as for Non-Hispanic Black persons, by sex and age group.

\*3HP SAT: 3 months of self-administered weekly doses of 900 mg of isoniazid and 900 mg of rifapentine; 4R SAT: 4 months of self-administered daily doses of 600 mg of rifampin.

# All MDR- and XDR-TB fall into the category of LTBI treatment failure.

† Annual and lifetime labor productivity estimates for future years are adjusted for a projected real income growth of 0.5%.

Abbreviations: IGRA = Interferon Gamma Release Assay, TST = Tuberculin Skin Test, HIV = Human Immunodeficiency Virus, LTBI = Latent Tuberculosis Infection, BMI = Body Mass Index, MDR TB = Multidrug-resistant tuberculosis, XDR TB = Extensively drug-resistant tuberculosis.

Supplement Table 3. Impact inventory form.

| Sector                      | Type of Impact (list category within each sector with unit of measure if relevant)  | Included in This Reference Case Analysis From...Perspective? |                    |          |
|-----------------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------|--------------------|----------|
|                             |                                                                                     | TB Service                                                   | Health Care Sector | Societal |
| Formal Health Care Sector   |                                                                                     |                                                              |                    |          |
| Health                      | Health outcomes (effects)                                                           |                                                              |                    |          |
|                             | Longevity effects                                                                   | Y                                                            | Y                  | Y        |
|                             | Health-related quality-of-life effects                                              | Y                                                            | Y                  | Y        |
|                             | Other health effects (eg, adverse events and secondary transmissions of infections) | Y                                                            | Y                  | Y        |
|                             | Medical costs                                                                       |                                                              |                    |          |
|                             | Paid for by third-party payers                                                      | Y                                                            | Y                  | Y        |
|                             | Paid for by patients out-of-pocket                                                  | Y                                                            | Y                  | Y        |
|                             | Future related medical costs (payers and patients)                                  | Y                                                            | Y                  | Y        |
|                             | Future unrelated medical costs (payers and patients)                                | N                                                            | Y                  | Y        |
| Informal Health Care Sector |                                                                                     |                                                              |                    |          |
| Health                      | Patient-time costs                                                                  | N                                                            | N                  | Y        |
|                             | Unpaid caregiver-time costs                                                         | N                                                            | N                  | Y        |
|                             | Transportation costs                                                                | N                                                            | N                  | Y        |
| Non-Health Care Sectors     |                                                                                     |                                                              |                    |          |
| Productivity                | Labor market earnings lost                                                          | N                                                            | N                  | Y        |
|                             | Cost of unpaid lost productivity due to illness                                     | N                                                            | N                  | Y        |
|                             | Cost of uncompensated household production                                          | N                                                            | N                  | Y        |
| Consumption                 | Future consumption unrelated to health                                              | N                                                            | N                  | Y        |
| Social Services             | Cost of social services as part of intervention                                     | N                                                            | N                  | Y        |
| Legal or Criminal Justice   | Number of crimes related to intervention                                            | NA                                                           | NA                 | NA       |
|                             | Cost of crimes related to intervention                                              | NA                                                           | NA                 | NA       |
| Education                   | Impact of intervention on educational achievement of population                     | N                                                            | N                  | Y        |
| Housing                     | Cost of intervention on home improvements (eg, removing lead paint)                 | N                                                            | N                  | Y        |
| Environment                 | Production of toxic waste pollution by intervention                                 | N                                                            | N                  | Y        |
| Food                        | Expenditures of food and alcoholic beverages                                        | N                                                            | N                  | Y        |
| Apparel and services        | Costs of clothes, footwear, and other apparel services                              | N                                                            | N                  | Y        |
| Transportation              | Transportation costs unrelated with health                                          | N                                                            | N                  | Y        |
| Entertainment               | Costs of audio and visual equipment and services, pets, toys, and hobbies,          | N                                                            | N                  | Y        |

Supplement Table 4. Number of populations, LTBI prevalence, and Medicare population with LTBI of Medicare population aged 65 years by risk factor in 2022.

| Group                                   | Population (million)    | LTBI prevalence‡ (%) | Population with LTBI (million) |
|-----------------------------------------|-------------------------|----------------------|--------------------------------|
| All groups                              | 2.00 (1.89, 2.14)       | 17.05 (14.14, 20.30) | 0.34 (0.28, 0.42)              |
| Group A <sup>a</sup>                    |                         |                      |                                |
| Total                                   | 0.99 (0.89, 1.10)       | 29.04 (24.25, 34.46) | 0.29 (0.23, 0.36)              |
| Non-US-born                             | 0.50 (0.40, 0.61)       | 40.40 (31.81, 50.25) | 0.20 (0.15, 0.27)              |
| History of homelessness <sup>†</sup>    | 0.23 (0.22, 0.23)       | 30.58 (25.48, 35.46) | 0.07 (0.06, 0.08)              |
| History of incarceration <sup>†</sup>   | 0.19 (0.18, 0.19)       | 16.97 (14.68, 19.26) | 0.03 (0.03, 0.04)              |
| Long-term care <sup>†</sup>             | 0.19 (0.18, 0.20)       | 19.66 (17.17, 22.25) | 0.04 (0.03, 0.04)              |
| Group B <sup>b</sup>                    |                         |                      |                                |
| Total                                   | 0.15 (0.14, 0.16)       | 9.89 (8.57, 11.25)   | 0.015 (0.013, 0.017)           |
| Close contact                           | 0.0007 (0.0005, 0.0009) | 24.43 (19.95, 29.57) | 0.0002 (0.0001, 0.0002)        |
| HIV                                     | 0.023 (0.019, 0.027)    | 14.50 (12.60, 16.58) | 0.003 (0.003, 0.004)           |
| Immunosuppressive medications recipient | 0.13 (0.12, 0.13)       | 8.95 (7.56, 10.38)   | 0.011 (0.010, 0.013)           |
| Organ transplant recipient              | 0.0012 (0.0011, 0.0013) | 12.60 (11.13, 14.09) | 0.0002 (0.0001, 0.0002)        |
| Group C <sup>c</sup>                    |                         |                      |                                |
| Total                                   | 1.33 (1.25, 1.41)       | 10.78 (9.36, 12.29)  | 0.14 (0.12, 0.16)              |
| Diabetes                                | 0.70 (0.68, 0.73)       | 12.22 (10.83, 13.63) | 0.09 (0.08, 0.10)              |
| End stage renal disease                 | 0.02 (0.003, 0.07)      | 11.13 (8.97, 13.59)  | 0.002 (0.0004, 0.008)          |
| Chronic kidney disease                  | 0.21 (0.16, 0.25)       | 9.69 (7.85, 11.82)   | 0.02 (0.01, 0.03)              |
| Cancer of the head, neck or blood       | 0.12 (0.08, 0.17)       | 9.95 (7.38, 12.96)   | 0.01 (0.008, 0.02)             |
| Gastrectomy                             | 0.004 (0.003, 0.005)    | 10.50 (9.25, 11.86)  | 0.0004 (0.0003, 0.0005)        |
| BMI under 20                            | 0.09 (0.06, 0.13)       | 9.87 (7.35, 12.75)   | 0.009 (0.006, 0.012)           |
| Current smoking                         | 0.41 (0.38, 0.44)       | 9.47 (7.83, 11.12)   | 0.04 (0.03, 0.05)              |

Values in parentheses represent 95% uncertainty intervals.

‡LTBI prevalence was estimated using estimates of IGRA+ prevalence, IGRA test sensitivity and specificity on the following equation:  $p(ltbi_i) = (p(igra_i) + spec_i - 1) / (sens_i + spec_i - 1)$ , where  $p(ltbi_i)$  is the LTBI prevalence in analytic stratum  $i$ ,  $p(igra_i)$  is the IGRA positive prevalence,  $sens_i$  and  $spec_i$  are the published estimates of IGRA test sensitivity and specificity for the same stratum.(15)

† LTBI prevalence for individuals with history of homelessness, history of incarceration, and long-term care were parameterized with LTBI prevalence reported in previous published studies.(63–65)

<sup>a</sup> Group A included those Medicare-eligible persons with one of four factors whom the USPSTF(14) recommends for screening and testing in the primary care setting for LTBI.

<sup>b</sup> Group B included those Medicare-eligible persons with one of four factors who acknowledged by USPSTF as population at risk for either exposure or progression to TB disease but regularly screened or tested outside of primary care settings.

<sup>c</sup> Group C included those Medicare-eligible persons with one of seven factors associated with increased risk of TB disease who are not specifically part of the USPSTF screening recommendation.

Supplement Table 5. Estimated numbers of LTBI treatment initiated, TB cases averted, TB deaths averted, and QALYs gained for LTBI testing and treatment intervention for Medicare-eligible persons aged 65 years or older and for persons aged 65 years in 2022.

| Health outcomes<br>in population group | Aged 65 years or older           | Aged 65 years              |
|----------------------------------------|----------------------------------|----------------------------|
| <b>LTBI treatment initiated</b>        |                                  |                            |
| Total                                  | 2,590,401 (2,121,043, 3,090,975) | 177,198 (143,883, 214,553) |
| Group A <sup>a</sup>                   | 1,840,447 (1,480,467, 2,261,964) | 129,516 (102,211, 163,075) |
| Group B <sup>b</sup>                   | 126,370 (105,689, 149,885)       | 9,183 (7,733, 10,815)      |
| Group C <sup>c</sup>                   | 1,380,328 (1,150,676, 1,632,761) | 88,207 (73,509, 103,721)   |
| <b>TB cases averted</b>                |                                  |                            |
| Total                                  | 10,946 (4,684, 20,579)           | 1,168 (491, 2,198)         |
| Group A <sup>a</sup>                   | 7,975 (3,433, 14,996)            | 869 (360, 1,706)           |
| Group B <sup>b</sup>                   | 419 (171, 846)                   | 56 (23, 107)               |
| Group C <sup>c</sup>                   | 3,314 (1,385, 6,648)             | 323 (130, 621)             |
| <b>TB deaths averted</b>               |                                  |                            |
| Total                                  | 2,579 (1,106, 4,882)             | 237 (102, 443)             |
| Group A <sup>a</sup>                   | 1,870 (801, 3,485)               | 175 (73, 329)              |
| Group B <sup>b</sup>                   | 83 (33, 170)                     | 10 (4, 21)                 |
| Group C <sup>c</sup>                   | 828 (338, 1,662)                 | 70 (29, 134)               |
| <b>QALYs gained</b>                    |                                  |                            |
| Total                                  | 13,234 (5343, 25,519)            | 1,632 (686, 3,152)         |
| Group A <sup>a</sup>                   | 10,235 (4,119, 19,978)           | 1,275 (517, 2,449)         |
| Group B <sup>b</sup>                   | 451 (164, 945)                   | 68 (26, 143)               |
| Group C <sup>c</sup>                   | 3,377 (1,274, 7,029)             | 392 (154, 778)             |

Values in parentheses represent 95% uncertainty intervals.

<sup>a</sup> Group A included those Medicare-eligible persons with one of four factors whom the USPSTF(14) recommends for screening and testing in the primary care setting for LTBI.

<sup>b</sup> Group B included those Medicare-eligible persons with one of four factors who acknowledged by USPSTF as population at risk for either exposure or progression to TB disease but regularly screened or tested outside of primary care settings.

<sup>c</sup> Group C included those Medicare-eligible persons with one of seven factors associated with increased risk of TB disease who are not specifically part of the USPSTF screening recommendation.

Supplement Table 6. Compared with no intervention, the estimated numbers of incremental costs (million in 2021 USD) from a TB service perspective, a healthcare perspective, and a societal perspective, for LTBI testing and treatment intervention for Medicare-eligible individuals aged 65 years or older, and for newly eligible for Medicare individuals aged 65 years in 2022.

| <b>Costs of LTBI testing and treatment from TB service perspective</b>  | <b>Aged 65 years or older</b> | <b>Aged 65 years</b> |
|-------------------------------------------------------------------------|-------------------------------|----------------------|
| Total                                                                   | \$2,040 (\$1,484, \$2,687)    | \$153 (\$110, \$205) |
| Group A <sup>a</sup>                                                    | \$1,270 (\$911, \$1,692)      | \$99 (\$70, \$136)   |
| Group B <sup>b</sup>                                                    | \$89 (\$63, \$122)            | \$8 (\$6, \$11)      |
| Group C <sup>c</sup>                                                    | \$896 (\$635, \$1,209)        | \$62 (\$44, \$84)    |
| <b>Costs of no intervention from TB service perspective</b>             | <b>Aged 65 years or older</b> | <b>Aged 65 years</b> |
| Total                                                                   | \$566 (\$237, \$1,069)        | \$62 (\$25, \$118)   |
| Group A <sup>a</sup>                                                    | \$407 (\$173, \$779)          | \$45 (\$18, \$89)    |
| Group B <sup>b</sup>                                                    | \$25 (\$10, \$49)             | \$3 (\$1, \$7)       |
| Group C <sup>c</sup>                                                    | \$174 (\$73, \$334)           | \$17 (\$7, \$34)     |
| <b>Incremental costs from different perspective in population group</b> | <b>Aged 65 years or older</b> | <b>Aged 65 years</b> |
| <b>TB service perspective</b>                                           |                               |                      |
| Total                                                                   | \$1,474 (\$966, \$2,059)      | \$91 (\$55, \$134)   |
| Group A <sup>a</sup>                                                    | \$863 (\$552, \$1,216)        | \$53 (\$30, \$81)    |
| Group B <sup>b</sup>                                                    | \$64 (\$41, \$94)             | \$5 (\$3, \$7)       |
| Group C <sup>c</sup>                                                    | \$721 (\$481, \$1,020)        | \$44 (\$28, \$65)    |
| <b>Healthcare perspective</b>                                           |                               |                      |
| Total                                                                   | \$1,715 (\$1,213, \$2,281)    | \$120 (\$85, \$160)  |
| Group A <sup>a</sup>                                                    | \$1,035 (\$734, \$1,396)      | \$74 (\$52, \$100)   |
| Group B <sup>b</sup>                                                    | \$76 (\$53, \$105)            | \$6 (\$4, \$9)       |
| Group C <sup>c</sup>                                                    | \$794 (\$554, \$1,101)        | \$52 (\$36, \$73)    |
| <b>Societal perspective</b>                                             |                               |                      |
| Total                                                                   | \$1,802 (\$1,298, \$2,377)    | \$119 (\$82, \$160)  |
| Group A <sup>a</sup>                                                    | \$1,126 (\$805, \$1,507)      | \$76 (\$53, \$104)   |
| Group B <sup>b</sup>                                                    | \$73 (\$49, \$104)            | \$5 (\$3, \$8)       |
| Group C <sup>c</sup>                                                    | \$797 (\$548, \$1,100)        | \$49 (\$33, \$70)    |

Values in parentheses represent 95% uncertainty intervals.

<sup>a</sup> Group A included those Medicare-eligible persons with one of four factors whom the USPSTF(14) recommends for screening and testing in the primary care setting for LTBI.

<sup>b</sup> Group B included those Medicare-eligible persons with one of four factors who acknowledged by USPSTF as population at risk for either exposure or progression to TB disease but regularly screened or tested outside of primary care settings.

<sup>c</sup> Group C included those Medicare-eligible persons with one of seven factors associated with increased risk of TB disease who are not specifically part of the USPSTF screening recommendation.

Supplement Table 7. Partial rank correlation coefficients identified parameters ordered from greatest to least influence on cost-effectiveness results.

| Parameters                                                                       | Coefficients | Uncertainty intervals |
|----------------------------------------------------------------------------------|--------------|-----------------------|
| Base rate of reactivation TB for individuals with LTBI in the overall population | -0.94        | (-0.96, -0.92)        |
| Cost of IGRA testing                                                             | 0.62         | (0.57, 0.67)          |
| Cost of LTBI treatment with 4R SAT                                               | 0.40         | (0.35, 0.46)          |
| Proportion tested with IGRA among US born                                        | 0.36         | (0.30, 0.42)          |
| Duration of TB disease prior to TB treatment                                     | -0.35        | (-0.41, -0.29)        |
| LTBI treatment efficacy                                                          | -0.23        | (-0.29, -0.17)        |
| IGRA test sensitivity: Non-US-born, HIV negative                                 | -0.17        | (-0.23, -0.10)        |
| Total cost of LTBI treatment with 3HP SAT*                                       | 0.15         | (0.09, 0.21)          |
| Ruling out TB disease before treatment initiation (Chest X-ray, 2 view)          | 0.14         | (0.08, 0.20)          |
| Probability of LTBI treatment hepatotoxicity                                     | 0.13         | (0.07, 0.20)          |
| IGRA test specificity: US-born, HIV negative                                     | -0.13        | (-0.19, -0.07)        |
| Cost of TST testing                                                              | 0.12         | (0.06, 0.18)          |
| Utility of TB disease and treatment                                              | 0.11         | (0.05, 0.17)          |
| Reactivation rate ratio: cancer                                                  | -0.10        | (-0.16, -0.04)        |
| Mortality rate ratio: diabetes                                                   | 0.09         | (0.03, 0.15)          |
| TST test specificity: US-born, HIV negative                                      | -0.09        | (-0.15, -0.03)        |
| Mortality rate ratio: cancer                                                     | 0.08         | (0.02, 0.14)          |
| Reactivation rate ratio: organ transplantation                                   | 0.08         | (0.02, 0.14)          |
| Reactivation rate ratio: close contact                                           | -0.08        | (-0.14, -0.01)        |
| TST test sensitivity: non-US-born, HIV negative                                  | -0.08        | (-0.13, -0.01)        |
| Cost of initial clinic visit                                                     | 0.07         | (0.01, 0.13)          |
| Proportion of treatment with 3HP                                                 | 0.07         | (0.01, 0.13)          |
| IGRA testing specificity: non-US-born, HIV negative                              | -0.07        | (-0.13, -0.004)       |
| Reactivation rate ratio: HIV                                                     | -0.06        | (-0.13, -0.002)       |
| LTBI treatment with hepatotoxicity utility                                       | -0.06        | (-0.12, 0.001)        |
| IGRA test sensitivity: US-born, HIV negative                                     | -0.06        | (-0.12, 0.001)        |
| Reactivation rate ratio: ESRD                                                    | -0.06        | (-0.12, 0.003)        |
| Proportion of LTBI treated who complete therapy                                  | -0.05        | (-0.11, 0.01)         |
| Mortality rate ratio: history of homelessness                                    | 0.05         | (-0.01, 0.11)         |
| Mortality rate ratio: organ transplantation                                      | 0.05         | (-0.02, 0.11)         |
| Mortality rate ratio: long-term care                                             | -0.04        | (-0.11, 0.02)         |
| IGRA testing specificity: US-born, HIV positive                                  | 0.04         | (-0.02, 0.11)         |
| TST test sensitivity: US-born, HIV negative                                      | -0.04        | (-0.11, 0.02)         |
| IGRA test sensitivity: non-US-born, HIV positive                                 | 0.04         | (-0.02, 0.10)         |
| Proportion accepting offer of LTBI testing                                       | -0.04        | (-0.10, 0.02)         |
| Reactivation rate ratio: diabetes                                                | -0.04        | (-0.10, 0.03)         |
| Probability of hospitalization with TB                                           | -0.04        | (-0.10, 0.03)         |
| IGRA test sensitivity: US-born, HIV positive                                     | -0.03        | (-0.10, 0.03)         |
| Cost of follow-up clinic visit                                                   | -0.03        | (-0.10, 0.03)         |
| TST test sensitivity: non-US born, HIV positive                                  | -0.03        | (-0.10, 0.03)         |
| Mortality rate ratio: BMI under 20                                               | 0.03         | (-0.03, 0.10)         |
| Direct treatment costs MDR TB                                                    | -0.03        | (-0.10, 0.03)         |
| Reactivation rate ratio: current smoking                                         | -0.03        | (-0.10, 0.03)         |
| TST test specificity: non-US-born, HIV negative                                  | 0.03         | (-0.04, 0.09)         |
| Mortality rate ratio: gastrectomy                                                | 0.03         | (-0.04, 0.09)         |
| Mortality rate ratio: ESRD                                                       | -0.02        | (-0.09, 0.04)         |
| Average duration of hospitalization with TB (in years)                           | -0.02        | (-0.08, 0.04)         |
| Mortality rate ratio: TB age 85 years and older                                  | 0.02         | (-0.04, 0.08)         |
| Reactivation rate: gastrectomy                                                   | 0.02         | (-0.04, 0.08)         |

|                                                               |        |               |
|---------------------------------------------------------------|--------|---------------|
| Time losses due to outpatient services (in years)             | 0.02   | (-0.04, 0.08) |
| Reactivation rate ratio: CKD                                  | -0.02  | (-0.08, 0.04) |
| Duration of hospitalization with LTBI treatment with 3HP      | 0.02   | (-0.04, 0.08) |
| Reactivation rate: immunosuppressive medication receipts      | -0.02  | (-0.08, 0.04) |
| Direct treatment costs XDR TB                                 | 0.02   | (-0.04, 0.08) |
| Proportion of TB that is MDR TB#                              | -0.02  | (-0.08, 0.04) |
| IGRA test specificity: non-US-born, HIV positive              | 0.02   | (-0.04, 0.08) |
| Mortality rate ratio: immunosuppressive medications recipient | -0.02  | (-0.08, 0.05) |
| Proportion of diagnosed who initiate treatment                | -0.02  | (-0.08, 0.05) |
| Mortality rate ratio: TB among age 75-84 years                | 0.01   | (-0.05, 0.08) |
| Mortality rate ratio: CKD                                     | 0.01   | (-0.05, 0.08) |
| Mortality rate ratio: TB aged 65-74 years                     | 0.01   | (-0.05, 0.07) |
| Mortality rate ratio: current smoking                         | 0.01   | (-0.05, 0.07) |
| TST test specificity: US-born, HIV positive                   | 0.01   | (-0.05, 0.07) |
| TST test specificity: non-US-born, HIV positive               | -0.01  | (-0.07, 0.05) |
| Mortality among individuals experiencing hepatotoxicity       | 0.005  | (-0.06, 0.07) |
| Reactivation rate ratio: BMI under 20                         | 0.004  | (-0.06, 0.07) |
| Probability of hospitalization with LTBI treatment with 3HP   | -0.004 | (-0.07, 0.06) |
| Proportion of TB that is XDR TB                               | -0.003 | (-0.07, 0.06) |
| Mortality rate ratio: HIV                                     | -0.001 | (-0.06, 0.06) |
| TST test sensitivity US born, HIV positive                    | 0.00   | (-0.06, 0.06) |

\*3HP SAT: 3 months of self-administered weekly doses of 900 mg of isoniazid and 900 mg of rifapentine; 4R SAT: 4 months of self-administered daily doses of 600 mg of rifampin.

# All MDR- and XDR-TB fall into the category of LTBI treatment failure.

Supplement Table 8. Compared with no intervention, the estimated incremental cost-effectiveness ratios by risk factor among the Medicare-eligible population aged 65 years or older in 2022.

| Group                                          | Main analysis                     | Sensitivity analyses              |                              |
|------------------------------------------------|-----------------------------------|-----------------------------------|------------------------------|
|                                                | Discount rate 3%                  | Discount rate 1.7%                | Discount rate 7%             |
| All groups                                     | 192,000 (92,000, 503,000)         | 166,000 (82,000, 429,000)         | 291,000 (137,000, 779,000)   |
| <b>Group A<sup>a</sup></b>                     |                                   |                                   |                              |
| Total                                          | 155,000 (77,000, 393,000)         | 134,000 (68,000, 331,000)         | 237,000 (114,000, 627,000)   |
| <i>Non-US-born</i>                             | 116,000 (59,000, 285,000)         | 101,000 (53,000, 244,000)         | 176,000 (84,000, 458,000)    |
| <i>History of homelessness</i>                 | 161,000 (68,000, 479,000)         | 138,000 (59,000, 409,000)         | 250,000 (108,000, 754,000)   |
| <i>History of incarceration</i>                | 227,000 (111,000, 603,000)        | 195,000 (97,000, 510,000)         | 351,000 (167,000, 979,000)   |
| <i>Long-term care</i>                          | 435,000 (205,000, 1,191,000)      | 380,000 (180,000, 1,020,000)      | 641,000 (294,000, 1,870,000) |
| <b>Group B<sup>b</sup></b>                     |                                   |                                   |                              |
| Total                                          | 220,000 (101,000, 638,000)        | 194,000 (90,000, 563,000)         | 318,000 (144,000, 942,000)   |
| <i>Close contact</i>                           | 26,000 (10,000, 78,000)           | 25,000 (12,000, 71,000)           | 30,000 (9,000, 105,000)      |
| <i>HIV</i>                                     | 39,000 (15,000, 114,000)          | 37,000 (15,000, 102,000)          | 52,000 (21,000, 160,000)     |
| <i>Immunosuppressive medications recipient</i> | 523,000 (212,000, 1,986,000)      | 453,000 (184,000, 1,707,000)      | 788,000 (312,000, 3,067,000) |
| <i>Organ transplant recipient</i>              | Dominant*<br>(Dominant*, 118,000) | Dominant*<br>(Dominant*, 104,000) | 6000<br>(Dominant*, 170,000) |
| <b>Group C<sup>c</sup></b>                     |                                   |                                   |                              |
| Total                                          | 324,000 (141,000, 922,000)        | 284,000 (125,000, 801,000)        | 472,000 (204,000, 1,415,000) |
| <i>Diabetes</i>                                | 417,000 (180,000, 1,290,000)      | 365,000 (159,000, 1,118,000)      | 608,000 (261,000, 2,049,000) |
| <i>End stage renal disease</i>                 | 340,000 (106,000, 2,086,000)      | 319,000 (98,000, 1,928,000)       | 427,000 (133,000, 2,331,000) |
| <i>Chronic kidney disease</i>                  | 443,000 (198,000, 1,606,000)      | 386,000 (174,000, 138,500)        | 656,000 (287,000, 2,523,000) |
| <i>Cancer of the head, neck or blood</i>       | 115,000 (40,000, 469,000)         | 102,000 (37,000, 412,000)         | 1,65,000 (60,000, 663,000)   |
| <i>Gastrectomy</i>                             | 238,000 (97,000, 751,000)         | 209,000 (86,000, 669,000)         | 348,000 (140,000, 1,088,000) |
| <i>BMI under 20</i>                            | 410,000 (137,000, 1,746,000)      | 362,000 (121,000, 1,517,000)      | 588,000 (196,000, 2,598,000) |
| <i>Current smoking</i>                         | 271,000 (120,000, 784,000)        | 236,000 (121,000, 1,517,000)      | 403,000 (177,000, 1,174,000) |

Values in parentheses represent 95% uncertainty intervals.

<sup>a</sup> Group A included those Medicare-eligible persons with one of four factors whom the USPSTF(14) recommends for screening and testing in the primary care setting for LTBI.

<sup>b</sup> Group B included those Medicare-eligible persons with one of four factors who acknowledged by USPSTF as population at risk for either exposure or progression to TB disease but regularly screened or tested outside of primary care settings.

<sup>c</sup> Group C included those Medicare-eligible persons with one of seven factors associated with increased risk of TB disease who are not specifically part of the USPSTF screening recommendation.

\*“Dominant” refers to an intervention that is both more effective (resulting in greater quality-adjusted life years [QALYs]) and less costly (lower lifetime costs) compared to the alternative strategy.

Supplement Table 9. Compared with no intervention, the estimated incremental cost-effectiveness ratios by risk factor among the Medicare-eligible population aged 65 years in 2022.

| Group                                          | Main analysis                 | Sensitivity analyses          |                                |
|------------------------------------------------|-------------------------------|-------------------------------|--------------------------------|
|                                                | Discount rate 3%              | Discount rate 1.7%            | Discount rate 7%               |
| All groups                                     | 109,000 (49,000, 285,000)     | 92,000 (43,000, 236,000)      | 181,000 (79,000, 491,000)      |
| <b>Group A<sup>a</sup></b>                     |                               |                               |                                |
| Total                                          | 89,000 (41,000, 228,000)      | 75,000 (36,000, 190,000)      | 150,000 (66,000, 414,000)      |
| <i>Non-US-born</i>                             | 72,000 (33,000, 183,000)      | 61,000 (30,000, 151,000)      | 120,000 (52,000, 321,000)      |
| <i>History of homelessness</i>                 | 126,000 (50,000, 396,000)     | 106,000 (42,000, 330,000)     | 208,000 (85,000, 634,000)      |
| <i>History of incarceration</i>                | 151,000 (70,000, 396,000)     | 126,000 (60,000, 327,000)     | 255,000 (115,000, 689,000)     |
| <i>Long-term care</i>                          | 180,000 (82,000, 484,000)     | 150,000 (70,000, 397,000)     | 307,000 (136,000, 844,000)     |
| <b>Group B<sup>b</sup></b>                     |                               |                               |                                |
| Total                                          | 113,000 (48,000, 333,000)     | 98,000 (43,000, 288,000)      | 174,000 (71,000, 515,000)      |
| <i>Close contact</i>                           | 9,000 (Dominant*, 51,000)     | 10,000 (Dominant*, 45,000)    | 11,000 (Dominant*, 75,000)     |
| <i>HIV</i>                                     | 23,000 (1,000, 76,000)        | 22,000 (100, 67,000)          | 33,000 (6,000, 115,000)        |
| <i>Immunosuppressive medications recipient</i> | 321,000 (121,000, 1,086,000)  | 270,000 (109,000, 932,000)    | 523,000 (211,000, 1,781,000)   |
| <i>Organ transplant recipient</i>              | Dominant* (Dominant*, 76,000) | Dominant* (Dominant*, 63,000) | Dominant* (Dominant*, 122,000) |
| <b>Group C<sup>c</sup></b>                     |                               |                               |                                |
| Total                                          | 185,000 (79,000, 513,000)     | 158,000 (68,000, 434,000)     | 295,000 (125,000, 838,000)     |
| <i>Diabetes</i>                                | 242,000 (100,000, 713,000)    | 207,000 (86,000, 605,000)     | 387,000 (160,000, 1,148,000)   |
| <i>End stage renal disease</i>                 | 161,000 (37,000, 916,000)     | 144,000 (29,000, 832,000)     | 220,000 (58,000, 1,190,000)    |
| <i>Chronic kidney disease</i>                  | 251,000 (117,000, 787,000)    | 213,000 (102,000, 657,000)    | 403,000 (179,000, 1,260,000)   |
| <i>Cancer of the head, neck or blood</i>       | 63,000 (17,000, 264,000)      | 54,000 (14,000, 225,000)      | 100,000 (30,000, 409,000)      |
| <i>Gastrectomy</i>                             | 138,000 (52,000, 434,000)     | 117,000 (44,000, 360,000)     | 223,000 (87,000, 678,000)      |
| <i>BMI under 20</i>                            | 206,000 (69,000, 859,000)     | 174,000 (59,000, 731,000)     | 332,000 (112,000, 1,361,000)   |
| <i>Current smoking</i>                         | 179,000 (75,000, 511,000)     | 152,000 (64,000, 431,000)     | 289,000 (124,000, 828,000)     |

Values in parentheses represent 95% uncertainty intervals.

<sup>a</sup> Group A included those Medicare-eligible persons with one of four factors whom the USPSTF(14) recommends for screening and testing in the primary care setting for LTBI.

<sup>b</sup> Group B included those Medicare-eligible persons with one of four factors acknowledged by USPSTF as populations at risk for either exposure or progression to TB disease but regularly screened or tested outside of primary care settings.

<sup>c</sup> Group C included those Medicare-eligible persons with one of seven factors associated with increased risk of TB disease who are not specifically part of the USPSTF screening recommendation.\*“Dominant” refers to an intervention that is both more effective (resulting in greater quality-adjusted life years [QALYs]) and less costly (lower lifetime costs) compared to the alternative strategy.

Supplement Table 10. Compared with no intervention, the estimated incremental cost-effectiveness ratios by risk factor among the Medicare-eligible population aged 65 years or older in 2022, with an alternative source for the base LTBI reactivation rate parameter.

| Group                                              | Main analysis                                                                  | Sensitivity analysis                                                           |
|----------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
|                                                    | Base LTBI reactivation rate<br>0.051 (0.031-0.102) per 100<br>person-years(18) | Base LTBI reactivation rate<br>0.084 (0.083-0.085) per 100<br>person-years(19) |
| All groups                                         | 192,000 (92,000, 503,000)                                                      | 117,000 (79,000, 168,000)                                                      |
| Group A <sup>a</sup>                               |                                                                                |                                                                                |
| Total                                              | 155,000 (77,000, 393,000)                                                      | 95,000 (66,000, 132,000)                                                       |
| <i>Non-US-born</i>                                 | 116,000 (59,000, 285,000)                                                      | 72,000 (51,000, 97,000)                                                        |
| <i>History of homelessness</i>                     | 161,000 (68,000, 479,000)                                                      | 91,000 (54,000, 157,000)                                                       |
| <i>History of incarceration</i>                    | 227,000 (111,000, 603,000)                                                     | 138,000 (93,000, 213,000)                                                      |
| <i>Long-term care</i>                              | 435,000 (205,000, 1,191,000)                                                   | 263,000 (177,000, 405,000)                                                     |
| Group B <sup>b</sup>                               |                                                                                |                                                                                |
| <b>Total</b>                                       | 220,000 (101,000, 638,000)                                                     | 133,000 (80,000, 231,000)                                                      |
| <i>Close contact</i>                               | 26,000 (10,000, 78,000)                                                        | 15,000 (7,000, 31,000)                                                         |
| <i>HIV</i>                                         | 39,000 (15,000, 114,000)                                                       | 24,000 (6,000, 40,000)                                                         |
| <i>Immunosuppressive medications<br/>recipient</i> | 523,000 (212,000, 1,986,000)                                                   | 313,000 (153,000, 744,000)                                                     |
| <i>Organ transplant recipient</i>                  | Dominant* (Dominant*,<br>118,000)                                              | Dominant*<br>(Dominant*, 29,000)                                               |
| Group C <sup>c</sup>                               |                                                                                |                                                                                |
| <b>Total</b>                                       | 324,000 (141,000, 922,000)                                                     | 195,000 (117,000, 337,000)                                                     |
| <i>Diabetes</i>                                    | 417,000 (180,000, 1,290,000)                                                   | 249,000 (137,000, 464,000)                                                     |
| <i>End stage renal disease</i>                     | 340,000 (106,000, 2,086,000)                                                   | 196,000 (72,000, 751,000)                                                      |
| <i>Chronic kidney disease</i>                      | 443,000 (198,000, 1,606,000)                                                   | 275,000 (151,000, 609,000)                                                     |
| <i>Cancer of the head, neck or blood</i>           | 115000 (40000, 469000)                                                         | 68000 (30000, 181000)                                                          |
| <i>Gastrectomy</i>                                 | 238000 (97000, 751000)                                                         | 141000 (79000, 294000)                                                         |
| <i>BMI under 20</i>                                | 410000 (137000, 1746000)                                                       | 247000 (110000, 719000)                                                        |
| <i>Current smoking</i>                             | 271000 (120000, 784000)                                                        | 161000 (96000, 281000)                                                         |

Values in parentheses represent 95% uncertainty intervals.

<sup>a</sup> Group A included those Medicare-eligible persons with one of four factors whom the USPSTF(14) recommends for screening and testing in the primary care setting for LTBI.

<sup>b</sup> Group B included those Medicare-eligible persons with one of four factors who acknowledged by USPSTF as population at risk for either exposure or progression to TB disease but regularly screened or tested outside of primary care settings.

<sup>c</sup> Group C included those Medicare-eligible persons with one of seven factors associated with increased risk of TB disease who are not specifically part of the USPSTF screening recommendation.

\*“Dominant” refers to an intervention that is both more effective (resulting in greater quality-adjusted life years [QALYs]) and less costly (lower lifetime costs) compared to the alternative strategy.

Supplement Table 11. Compared with no intervention, the estimated incremental cost-effectiveness ratios by risk factor among the Medicare-eligible population aged 65 years or older in 2022, with 100% of accepting LTBI testing, 100% of initiating treatment among who diagnosed with LTBI, and 100% of completing therapy.

| Group                                          | Main analysis                                                                                                                                                  | Sensitivity analysis                                                                                                                               |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                | Proportion of accepting LTBI testing 0.762(31); proportion of diagnosed who initiate treatment 0.762(32); proportion of treated who complete therapy 0.903(33) | Proportion of accepting LTBI testing 1.000; proportion of diagnosed who initiate treatment 1.000; proportion of treated who complete therapy 1.000 |
| All groups                                     | 192,000 (92,000, 503,000)                                                                                                                                      | 145,000 (72,000, 373,000)                                                                                                                          |
| <b>Group A<sup>a</sup></b>                     |                                                                                                                                                                |                                                                                                                                                    |
| Total                                          | 155,000 (77,000, 393,000)                                                                                                                                      | 124,000 (63,000, 311,000)                                                                                                                          |
| <i>Non-US-born</i>                             | 116,000 (59,000, 285,000)                                                                                                                                      | 97,000 (49,000, 235,000)                                                                                                                           |
| <i>History of homelessness</i>                 | 161,000 (68,000, 479,000)                                                                                                                                      | 124,000 (53,000, 373,000)                                                                                                                          |
| <i>History of incarceration</i>                | 227,000 (111,000, 603,000)                                                                                                                                     | 167,000 (84,000, 438,000)                                                                                                                          |
| <i>Long-term care</i>                          | 435,000 (205,000, 1,191,000)                                                                                                                                   | 321,000 (157,000, 869,000)                                                                                                                         |
| <b>Group B<sup>b</sup></b>                     |                                                                                                                                                                |                                                                                                                                                    |
| <b>Total</b>                                   | 220,000 (101,000, 638,000)                                                                                                                                     | 151,000 (70,000, 441,000)                                                                                                                          |
| <i>Close contact</i>                           | 26,000 (10,000, 78,000)                                                                                                                                        | 20,000 (7,000, 61,000)                                                                                                                             |
| <i>HIV</i>                                     | 39,000 (15,000, 114,000)                                                                                                                                       | 27,000 (7,000, 74,000)                                                                                                                             |
| <i>Immunosuppressive medications recipient</i> | 523,000 (212,000, 1,986,000)                                                                                                                                   | 360,000 (149,000, 1,283,000)                                                                                                                       |
| <i>Organ transplant recipient</i>              | Dominant* (Dominant*, 118,000)                                                                                                                                 | Dominant* (Dominant*, 71,000)                                                                                                                      |
| <b>Group C<sup>c</sup></b>                     |                                                                                                                                                                |                                                                                                                                                    |
| <b>Total</b>                                   | 324,000 (141,000, 922,000)                                                                                                                                     | 292,000 (130,000, 911,000)                                                                                                                         |
| <i>Diabetes</i>                                | 417,000 (180,000, 1,290,000)                                                                                                                                   | 271,000 (122,000, 814,000)                                                                                                                         |
| <i>End stage renal disease</i>                 | 340,000 (106,000, 2,086,000)                                                                                                                                   | 230,000 (72,000, 1,365,000)                                                                                                                        |
| <i>Chronic kidney disease</i>                  | 443,000 (198,000, 1,606,000)                                                                                                                                   | 317,000 (149,000, 1,108,000)                                                                                                                       |
| <i>Cancer of the head, neck or blood</i>       | 115,000 (40,000, 469,000)                                                                                                                                      | 78,000 (26,000, 312,000)                                                                                                                           |
| <i>Gastrectomy</i>                             | 238,000 (97,000, 751,000)                                                                                                                                      | 164,000 (69,000, 521,000)                                                                                                                          |
| <i>BMI under 20</i>                            | 410,000 (137,000, 1,746,000)                                                                                                                                   | 283,000 (96,000, 1,174,000)                                                                                                                        |
| <i>Current smoking</i>                         | 271,000 (120,000, 784,000)                                                                                                                                     | 187,000 (84,000, 543,000)                                                                                                                          |

Values in parentheses represent 95% uncertainty intervals.

<sup>a</sup> Group A included those Medicare-eligible persons with one of four factors whom the USPSTF(14) recommends for screening and testing in the primary care setting for LTBI.

<sup>b</sup> Group B included those Medicare-eligible persons with one of four factors who acknowledged by USPSTF as population at risk for either exposure or progression to TB disease but regularly screened or tested outside of primary care settings.

<sup>c</sup> Group C included those Medicare-eligible persons with one of seven factors associated with increased risk of TB disease who are not specifically part of the USPSTF screening recommendation.

\*“Dominant” refers to an intervention that is both more effective (resulting in greater quality-adjusted life years [QALYs]) and less costly (lower lifetime costs) compared to the alternative strategy.

Supplement Table 12. Compared with no intervention, the estimated incremental cost-effectiveness ratios by risk factor among the Medicare-eligible population aged 65 years or older in 2022, with IGRA and TST tests characteristics from USPSTF(14).

| Group                                          | Main analysis                                            | Sensitivity analysis                               |
|------------------------------------------------|----------------------------------------------------------|----------------------------------------------------|
|                                                | IGRA and TST tests characteristics from Stout et al.(15) | IGRA and TST tests characteristics from USPSTF(14) |
| All groups                                     | 192,000 (92,000, 503,000)                                | 169,000 (81,000, 436,000)                          |
| Group A <sup>a</sup>                           |                                                          |                                                    |
| Total                                          | 155,000 (77,000, 393,000)                                | 145,000 (72,000, 361,000)                          |
| <i>Non-US-born</i>                             | 116,000 (59,000, 285,000)                                | 114,000 (57,000, 278,000)                          |
| <i>History of homelessness</i>                 | 161,000 (68,000, 479,000)                                | 141,000 (60,000, 429,000)                          |
| <i>History of incarceration</i>                | 227,000 (111,000, 603,000)                               | 190,000 (91,000, 498,000)                          |
| <i>Long-term care</i>                          | 435,000 (205,000, 1,191,000)                             | 363,000 (169,000, 965,000)                         |
| Group B <sup>b</sup>                           |                                                          |                                                    |
| <b>Total</b>                                   | 220,000 (101,000, 638,000)                               | 170,000 (78,000, 490,000)                          |
| <i>Close contact</i>                           | 26,000 (10,000, 78,000)                                  | 2,400 (9,000, 72,000)                              |
| <i>HIV</i>                                     | 39,000 (15,000, 114,000)                                 | 31,000 (10,000, 86,000)                            |
| <i>Immunosuppressive medications recipient</i> | 523,000 (212,000, 1,986,000)                             | 446,000 (181,000, 1,640,000)                       |
| <i>Organ transplant recipient</i>              | Dominant*<br>(Dominant*, 118,000)                        | Dominant*<br>(Dominant*, 96,000)                   |
| Group C <sup>c</sup>                           |                                                          |                                                    |
| <b>Total</b>                                   | 324,000 (141,000, 922,000)                               | 258,000 (112,000, 715,000)                         |
| <i>Diabetes</i>                                | 417,000 (180,000, 1,290,000)                             | 332,000 (145,000, 973,000)                         |
| <i>End stage renal disease</i>                 | 340,000 (106,000, 2,086,000)                             | 268,000 (78,000, 1,505,000)                        |
| <i>Chronic kidney disease</i>                  | 443,000 (198,000, 1,606,000)                             | 356,000 (159,000, 1,115,000)                       |
| <i>Cancer of the head, neck or blood</i>       | 115,000 (40,000, 469,000)                                | 91,000 (32,000, 360,000)                           |
| <i>Gastrectomy</i>                             | 238,000 (97,000, 751,000)                                | 188,000 (76,000, 580,000)                          |
| <i>BMI under 20</i>                            | 410,000 (137,000, 1,746,000)                             | 324,000 (111,000, 1,307,000)                       |
| <i>Current smoking</i>                         | 271,000 (120,000, 784,000)                               | 215,000 (93,000, 570,000)                          |

Values in parentheses represent 95% uncertainty intervals.

<sup>a</sup> Group A included those Medicare-eligible persons with one of four factors whom the USPSTF(14) recommends for screening and testing in the primary care setting for LTBI.

<sup>b</sup> Group B included those Medicare-eligible persons with one of four factors who acknowledged by USPSTF as population at risk for either exposure or progression to TB disease but regularly screened or tested outside of primary care settings.

<sup>c</sup> Group C included those Medicare-eligible persons with one of seven factors associated with increased risk of TB disease who are not specifically part of the USPSTF screening recommendation.


\*“Dominant” refers to an intervention that is both more effective (resulting in greater quality-adjusted life years [QALYs]) and less costly (lower lifetime costs) compared to the alternative strategy.

Supplement Table 13. Compared with no intervention, the estimated incremental cost-effectiveness ratios by risk factor among the Medicare-eligible population aged 65 years or older in 2022, when considering the consequences of averted secondary TB cases.

| Group                                          | Main analysis                     | Sensitivity analysis          |
|------------------------------------------------|-----------------------------------|-------------------------------|
|                                                | Secondary TB cases NOT considered | Secondary TB cases considered |
| All groups                                     | 192,000 (92,000, 503,000)         | 161,000 (74,000, 426,000)     |
| Group A <sup>a</sup>                           |                                   |                               |
| Total                                          | 155,000 (77,000, 393,000)         | 129,000 (61,000, 337,000)     |
| <i>Non-US-born</i>                             | 116,000 (59,000, 285,000)         | 95,000 (45,000, 238,000)      |
| <i>History of homelessness</i>                 | 161,000 (68,000, 479,000)         | 131,000 (50,000, 413,000)     |
| <i>History of incarceration</i>                | 227,000 (111,000, 603,000)        | 191,000 (89,000, 516,000)     |
| <i>Long-term care</i>                          | 435,000 (205,000, 1,191,000)      | 374,000 (171,000, 1,065,000)  |
| Group B <sup>b</sup>                           |                                   |                               |
| <b>Total</b>                                   | 220,000 (101,000, 638,000)        | 183,000 (77,000, 559,000)     |
| <i>Close contact</i>                           | 26,000 (10,000, 78,000)           | 16,000 (2,000, 61,000)        |
| <i>HIV</i>                                     | 39,000 (15,000, 114,000)          | 24,000 (1,000, 87,000)        |
| <i>Immunosuppressive medications recipient</i> | 523,000 (212,000, 1,986,000)      | 449,000 (176,000, 1,712,000)  |
| <i>Organ transplant recipient</i>              | Dominant* (Dominant*, 118,000)    | Dominant* (Dominant*, 83,000) |
| Group C <sup>c</sup>                           |                                   |                               |
| <b>Total</b>                                   | 324,000 (141,000, 922,000)        | 335,000 (150,000, 1,117,000)  |
| <i>Diabetes</i>                                | 417,000 (180,000, 1,290,000)      | 268,000 (61,000, 1,729,000)   |
| <i>End stage renal disease</i>                 | 340,000 (106,000, 2,086,000)      | 380,000 (167,000, 1,391,000)  |
| <i>Chronic kidney disease</i>                  | 443,000 (198,000, 1,606,000)      | 340,000 (142,000, 1,176,000)  |
| <i>Cancer of the head, neck or blood</i>       | 115,000 (40,000, 469,000)         | 92,000 (27,000, 398,000)      |
| <i>Gastrectomy</i>                             | 238,000 (97,000, 751,000)         | 199,000 (77,000, 660,000)     |
| <i>BMI under 20</i>                            | 410,000 (137,000, 1,746,000)      | 350,000 (111,000, 1,547,000)  |
| <i>Current smoking</i>                         | 271,000 (120,000, 784,000)        | 228,000 (96,000, 672,000)     |

\*“Dominant” refers to an intervention that is both more effective (resulting in greater quality-adjusted life years [QALYs]) and less costly (lower lifetime costs) compared to the alternative strategy.

Supplement Figure 1. Decision tree and Markov model of the lifetime progression of a Medicare cohort for LTBI screening and treatment.




\*Modelled population stratified by age, sex, race-ethnicity, and risk factor for TB progression.

§ Includes TST test and IGRA test.

False positives are defined as individuals who test positive for LTBI despite not being infected.

Supplement Figure 2. Cost-effectiveness acceptability curves for the intervention offered to the overall target population aged 65 years over, and for risk factor Groups A, B, and C.



Group total included those Medicare-eligible persons with one of fifteen factors whom the USPSTF(14) recommends for screening and testing in the primary care setting for LTBI.


Group A included those Medicare-eligible persons with one of four factors whom the USPSTF(14) recommends for screening and testing in the primary care setting for LTBI.

Group B included those Medicare-eligible persons with one of four factors who acknowledged by USPSTF as population at risk for either exposure or progression to TB disease but regularly screened or tested outside of primary care settings.

Group C included those Medicare-eligible persons with one of seven factors associated with increased risk of TB disease who are not specifically part of the USPSTF screening recommendation.

According to this figure, there was a 28.1% probability that the ICER would fall below \$150,000 per QALY for the intervention provided to persons with at least one TB risk factor. This probability was 45.4% for individuals with Group A risk factors.

Supplement Figure 3. Cost-effectiveness acceptability curves for the intervention offered to the overall target population aged 65 years, and for risk factor Groups A, B, and C.



Group total included those Medicare-eligible persons with one of fifteen factors whom the USPSTF(14) recommends for screening and testing in the primary care setting for LTBI.

Group A included those Medicare-eligible persons with one of four factors whom the USPSTF(14) recommends for screening and testing in the primary care setting for LTBI.

Group B included those Medicare-eligible persons with one of four factors who acknowledged by USPSTF as population at risk for either exposure or progression to TB disease but regularly screened or tested outside of primary care settings.

Group C included those Medicare-eligible persons with one of seven factors associated with increased risk of TB disease who are not specifically part of the USPSTF screening recommendation.

## References

1. NHIS - National Health Interview Survey [Internet]. 2022 [cited 2022 Jan 9]. Available from: <https://www.cdc.gov/nchs/nhis/index.htm>
2. Centers for Disease Control and Prevention. NHANES - National Health and Nutrition Examination Survey Homepage [Internet]. 2022 [cited 2021 Dec 20]. Available from: <https://www.cdc.gov/nchs/nhanes/index.htm>
3. National Center for Health Statistics (U.S.), editor. Long-term care providers and services users in the United States, 2015-2016. Washington, DC: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2019. (DHHS publication).
4. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2015–2019. HIV Surveillance Supplemental Report 2021;26(No. 1). 2021 May;26(1):81.
5. Centers for Disease Control and Prevention. Diagnoses of HIV infection among adults aged 50 years and older in the United States and dependent areas, 2011–2016. HIV Surveillance Supplemental Report 2018;23(No. 5). 2018 Aug;24(1):89.
6. OPTN: Organ Procurement and Transplantation Network - OPTN [Internet]. [cited 2022 Aug 19]. Available from: <https://optn.transplant.hrsa.gov/>
7. American Society for Metabolic and Bariatric Surgery estimation of metabolic and bariatric procedures performed in the United States in 2016 - ClinicalKey [Internet]. [cited 2022 Aug 19]. Available from: <https://www-clinicalkey-com.ezp-prod1.hul.harvard.edu/#!/content/playContent/1-s2.0-S155072891731095X?returnurl=null&referrer=null>
8. Garcia-Grossman IR, Cenzer I, Steinman MA, Williams BA. History of Incarceration and Its Association With Geriatric and Chronic Health Outcomes in Older Adulthood. JAMA Network Open. 2023 Jan 6;6(1):e2249785.
9. Fusaro VA, Levy HG, Shaefer HL. Racial and Ethnic Disparities in the Lifetime Prevalence of Homelessness in the United States. Demography. 2018 Dec;55(6):2119–28.
10. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016 Sep 13;316(10):1093–103.
11. American Community Survey Data [Internet]. [cited 2022 Feb 24]. Available from: <https://www.census.gov/programs-surveys/acs/data.html>
12. [1906.01716] High-resolution estimates of the foreign-born population and international migration for the United States [Internet]. [cited 2022 Jan 16]. Available from: <https://arxiv.org/abs/1906.01716>

13. Centers for Disease Control and Prevention. Diagnoses of HIV Infection in the United States and Dependent Areas, 2020 [Internet]. [cited 2023 Mar 18]. Report No.: 33. Available from: <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>
14. US Preventive Services Task Force. Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2023 May 2;329(17):1487–94.
15. Stout JE, Wu Y, Ho CS, Pettit AC, Feng PJ, Katz DJ, et al. Evaluating latent tuberculosis infection diagnostics using latent class analysis. *Thorax*. 2018 Nov 1;73(11):1062–70.
16. CDC. Tuberculosis (TB). 2024 [cited 2024 Oct 6]. Clinical Testing Guidance for Tuberculosis: Tuberculin Skin Test. Available from: <https://www.cdc.gov/tb/hcp/testing-diagnosis/tuberculin-skin-test.html>
17. Jonas DE, Riley SR, Lee LC, Coffey CP, Wang SH, Asher GN, et al. Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*. 2023 May 2;329(17):1495–509.
18. Ekramnia M, Li Y, Haddad MB, Hill AH, Marks SM, Swartwood NA, et al. Latent TB reactivation rates for TB risk populations in the United States. *Epidemiology*. :Accepted.
19. Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. *Am J Epidemiol*. 2014 Jan 15;179(2):216–25.
20. Centers for Disease Control and Prevention. Latent Tuberculosis Infection: A Guide for Primary Health Care Providers [Internet]. Available from: <https://www.cdc.gov/tb/publications/ltbi/pdf/LTBIbooklet508.pdf>
21. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Bauman L, Davidson KW, et al. Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2016 Sep 6;316(9):962.
22. Ferebee SH, Mount FW. Tuberculosis Morbidity in a Controlled Trial of the Prophylactic Use of Isoniazid among Household Contacts. *Am Rev Respir Dis*. 1962 Apr;85(4):490–510.
23. Paul Brassard, Kezouh A, Suissa S. Antirheumatic Drugs and the Risk of Tuberculosis. *Clinical Infectious Diseases*. 2006 Sep 15;43(6):717–22.
24. Sidhu A, Verma G, Humar A, Kumar D. Outcome of Latent Tuberculosis Infection in Solid Organ Transplant Recipients Over a 10-Year Period. *Transplantation*. 2014 Sep 27;98(6):671.
25. Ruzangi J, Iwagami M, Smeeth L, Mangtani P, Nitsch D. The association between chronic kidney disease and tuberculosis; a comparative cohort study in England. *BMC Nephrol*. 2020 Oct 1;21:420.

26. Nanthanangkul S, Promthet S, Suwanrungruang K, Santong C, Vatanasapt P. Incidence of and Risk Factors for Tuberculosis among Cancer Patients in Endemic Area: A Regional Cohort Study. *Asian Pac J Cancer Prev*. 2020 Sep;21(9):2715–21.
27. Park HY, Choi SH, Kim D, Hwang J, Kwon Y, Kwon JW. Incidence and risk factors of tuberculosis in patients following gastrectomy or endoscopic submucosal dissection: a cohort analysis of country-level data. *Gastric Cancer* [Internet]. 2023 Jan 25 [cited 2023 Mar 19]; Available from: <https://doi.org/10.1007/s10120-023-01367-4>
28. Cheng J, Sun YN, Zhang CY, Yu YL, Tang LH, Peng H, et al. Incidence and risk factors of tuberculosis among the elderly population in China: a prospective cohort study. *Infectious Diseases of Poverty*. 2020 Feb;09(01):64–76.
29. Soh AZ, Chee CBE, Wang YT, Yuan JM, Koh WP. Alcohol drinking and cigarette smoking in relation to risk of active tuberculosis: prospective cohort study. *BMJ Open Respiratory Research*. 2017 Oct 1;4(1):e000247.
30. Vonnahme LA, Haddad MB, Navin TR. Factoring Prior Treatment into Tuberculosis Infection Prevalence Estimates, United States, 2011–2012. *Emerging Infectious Diseases*. 2019 Oct;25(10):1949.
31. Centers for Disease Control and Prevention, Division of Tuberculosis Elimination. The Aggregate Reports for Tuberculosis Program Evaluation (ARPE) report 2023.
32. 2020 State and City TB Report | Data & Statistics | TB | CDC [Internet]. 2022 [cited 2022 Oct 28]. Available from: <https://www.cdc.gov/tb/statistics/indicators/2020/StateCity-TBReport.htm>
33. Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, et al. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection. *Clinical Infectious Diseases*. 2017 Oct 1;65(7):1085–93.
34. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. *Bull World Health Organ*. 1982;60(4):555–64.
35. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection. *New England Journal of Medicine*. 2011 Dec 8;365(23):2155–66.
36. Sterling TR. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. *MMWR Recomm Rep* [Internet]. 2020 [cited 2024 Sep 30];69. Available from: <https://www.cdc.gov/mmwr/volumes/69/rr/rr6901a1.htm>

37. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. *Am J Respir Crit Care Med*. 2006 Oct 15;174(8):935–52.
38. Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, et al. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. *Int J Tuberc Lung Dis*. 2015 Sep;19(9):1039–v.
39. Centers for Disease Control and Prevention, National Center for Health Statistics. Provisional Multiple Cause of Death by Single Race, Multiple Cause of Death Data on CDC WONDER [Internet]. [cited 2022 Nov 6]. Available from: <https://wonder.cdc.gov/mcd-icd10-provisional.html>
40. Brown RT, Evans JL, Valle K, Guzman D, Chen YH, Kushel MB. Factors Associated With Mortality Among Homeless Older Adults in California: The HOPE HOME Study. *JAMA Internal Medicine*. 2022 Oct 1;182(10):1052–60.
41. Kim D, Park C, Briesacher BA. Socially-isolated neighborhoods and the risk of all-cause mortality among nursing home residents in the United States: A multilevel study. *Preventive Medicine Reports*. 2021 Mar 1;21:101285.
42. Magliano DJ, Chen L, Carstensen B, Gregg EW, Pavkov ME, Salim A, et al. Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data. *The Lancet Diabetes & Endocrinology*. 2022 Feb 1;10(2):112–9.
43. Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. *The Lancet*. 2012 Nov;380(9854):1649–61.
44. Kvaloy JM, Holmen J, Wilsgaard T, Florholmen J, Midthjell K, Jacobsen BK. Body mass index and mortality in elderly men and women: the Tromsø and HUNT studies. *J Epidemiol Community Health*. 2012 Jul;66(7):611–7.
45. Gellert C, Schöttker B, Brenner H. Smoking and All-Cause Mortality in Older People: Systematic Review and Meta-analysis. *Archives of Internal Medicine*. 2012 Jun 11;172(11):837–44.
46. Arias E, Xu J. United States Life tables, 2018. Hyattsville, MD: National Center for Health Statistics; 2020. (National Vital Statistics Reports). Report No.: Vol 69, no 12.
47. Guo N, Marra CA, Marra F, Moadebi S, Elwood RK, FitzGerald JM. Health State Utilities in Latent and Active Tuberculosis. *Value in Health [Internet]*. 2008 [cited 2022 Oct 25];11(7). Available from: <https://www-clinicalkey-com.ezp-prod1.hul.harvard.edu/#!/content/playContent/1-s2.0-S1098301510605979>

48. McLernon DJ, Dillon J, Donnan PT. Systematic Review: Health-State Utilities in Liver Disease: A Systematic Review. *Med Decis Making*. 2008 Jul 1;28(4):582–92.
49. Menzies NA, Shrestha S, Parriott A, Marks SM, Hill AN, Dowdy DW, et al. The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease. *Epidemiology*. 2022 Jan 1;33(1):75–83.
50. 2020 | CMS [Internet]. [cited 2022 Oct 28]. Available from: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Annual-Policy-Files-Items/2020-Annual-Policy-Files>
51. Support EWA. VA National Acquisition Center Contract Catalog Search Tool [Internet]. [cited 2022 Oct 28]. Available from: <https://www.vendorportal.ecms.va.gov/nac/Pharma/List>
52. Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, et al. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. *Int J Tuberc Lung Dis*. 2013 Dec;17(12):1531–7.
53. Feng PJI, Horne DJ, Wortham JM, Katz DJ, CDC Tuberculosis Epidemiologic Studies Consortium. Trends in tuberculosis clinicians’ adoption of short-course regimens for latent tuberculosis infection. *J Clin Tuberc Other Mycobact Dis*. 2023 Dec;33:100382.
54. Centers for Disease Control and Prevention. CDC Estimates for TB Treatment Costs (in 2020 U.S. Dollars) [Internet]. 2022 [cited 2023 Mar 29]. Available from: <https://www.cdc.gov/tb/publications/infographic/appendix.htm>
55. Marks SM, Winston CA. Estimated treatment costs for multidrug-resistant TB in the United States. *The International Journal of Tuberculosis and Lung Disease*. 2024 Apr 1;28(4):214–5.
56. CDCTB. Centers for Disease Control and Prevention. 2021 [cited 2022 Oct 28]. Reported TB in the U.S., 2020- Executive Commentary. Available from: [https://www.cdc.gov/tb/statistics/reports/2020/Exec\\_Commentary.html](https://www.cdc.gov/tb/statistics/reports/2020/Exec_Commentary.html)
57. Grosse SD, Krueger KV, Pike J. Estimated annual and lifetime labor productivity in the United States, 2016: implications for economic evaluations. *Journal of Medical Economics*. 2019 Jun 3;22(6):501–8.
58. U.S. Bureau of Labor Statistics. Age of reference person: Annual expenditure means, shares, standard errors, and coefficients of variation, Consumer Expenditure Surveys, 2021 [Internet]. 2022 Sep. Available from: <https://www.bls.gov/cex/tables/calendar-year/mean-item-share-average-standard-error/reference-person-age-ranges-2021.pdf>
59. Jiao B, Basu A. Catalog of Age- and Medical Condition-Specific Healthcare Costs in the United States to Inform Future Costs Calculations in Cost-Effectiveness Analysis. *Value Health*. 2021 Jul;24(7):957–65.

60. Bingham A, Shrestha RK, Khurana N, Jacobson EU, Farnham PG. Estimated Lifetime HIV–Related Medical Costs in the United States. *Sexually Transmitted Diseases*. 2021 Apr;48(4):299.
61. United States Renal Data System. 2023 USRDS Annual Data Report: Epidemiology of kidney disease in the United States [Internet]. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD %8, 2023; Available from: <https://adr.usrds.org/2023>
62. James A, Mannon RB. The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable? *Curr Transplant Rep*. 2015 Jun 1;2(2):113–21.
63. McAdam JM, Bucher SJ, Brickner PW, Vincent RL, Lascher S. Latent Tuberculosis and Active Tuberculosis Disease Rates among the Homeless, New York, New York, USA, 1992–2006. *Emerg Infect Dis*. 2009 Jul;15(7):1109–11.
64. Lobato MN, Leary LS, Simone PM. Treatment for latent TB in correctional facilities: A challenge for TB elimination. *American Journal of Preventive Medicine*. 2003 Apr 1;24(3):249–53.
65. Reddy D, Walker J, White LF, Brandeis GH, Russell ML, Horsburgh Jr CR, et al. Latent Tuberculosis Infection Testing Practices in Long-Term Care Facilities, Boston, Massachusetts. *Journal of the American Geriatrics Society*. 2017;65(6):1145–51.